MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Cytori Therapeutics Company Profile (NASDAQ:CYTX)

Consensus Ratings for Cytori Therapeutics (NASDAQ:CYTX) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $48.75 (2,313.37% upside)

Analysts' Ratings History for Cytori Therapeutics (NASDAQ:CYTX)
Show:
DateFirmActionRatingPrice TargetActions
3/31/2016Maxim GroupReiterated RatingBuy$75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/28/2016Roth CapitalInitiated CoverageBuy$22.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2015Ascendiant Capital MarketsInitiated CoverageBuy$18.75View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/7/2015LaidlawReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for Cytori Therapeutics (NASDAQ:CYTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/10/2016Q1($0.03)($0.41)$2.05 million$2.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2016Q4($0.04)($0.03)$1.56 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.06)($0.04)$5.27 million$2.48 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.03)($0.06)$2.50 million$1.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.07)($0.07)$2.44 million$0.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q4 14($0.08)($0.08)$3.10 million$2.47 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014($0.09)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014($0.11)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.14)($0.14)$2.87 million$1.03 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2014Q413($0.12)($0.14)$4.37 million$2.71 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013Q313($0.11)($0.08)$3.17 million$8.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013($0.13)($0.16)$2.88 million$6.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013($0.16)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q312($0.15)($0.19)$2.25 million$1.31 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Cytori Therapeutics (NASDAQ:CYTX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($7.35)($7.35)($7.35)
Q3 20161($7.05)($7.05)($7.05)
Q4 20161($8.25)($8.25)($8.25)
(Data provided by Zacks Investment Research)
Dividend History for Cytori Therapeutics (NASDAQ:CYTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Cytori Therapeutics (NASDAQ:CYTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/14/2016Gail K NaughtonDirectorBuy1,000$2.10$2,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2016John David HarrisVPBuy2,000$2.71$5,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2016David RickeyDirectorBuy150,000$0.19$28,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2015Tommy G ThompsonDirectorBuy25,449$0.37$9,416.13View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2015Jeremy B HaydenVPBuy8,200$0.36$2,952.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2015David RickeyDirectorBuy56,000$0.31$17,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2015Marc H HedrickCEOBuy11,200$0.31$3,472.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2015David RickeyDirectorBuy75,000$0.31$23,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2015David RickeyDirectorBuy50,000$0.38$19,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2015Marc H HedrickCEOBuy5,000$0.38$1,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Marc H HedrickCEOBuy10,000$0.40$4,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2015David RickeyDirectorBuy48,600$0.39$18,954.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2015Steven KestenVPBuy6,000$0.39$2,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015David RickeyDirectorBuy51,400$0.39$20,046.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Marc H HedrickCEOBuy10,000$0.39$3,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Tiago GiraoCFOBuy25,000$0.39$9,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014David RickeyDirectorBuy20,000$0.47$9,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014David RickeyDirectorBuy200,000$0.39$78,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Tiago GiraoCFOBuy60,000$0.39$23,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2014Tiago GiraoCFOBuy15,889$0.39$6,196.71View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2014David RickeyDirectorBuy30,000$2.34$70,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2013David RickeyDirectorBuy7,100$2.55$18,105.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2013David RickeyDirectorBuy2,000$2.58$5,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2013David RickeyDirectorBuy5,000$2.31$11,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/5/2013David RickeyDirectorBuy2,000$2.24$4,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013David RickeyDirectorBuy7,000$2.14$14,980.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/30/2013Tommy G ThompsonDirectorBuy5,000$2.14$10,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2012Lloyd H DeanDirectorBuy25,000$2.85$71,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2012Marc H HedrickPresidentBuy10,000$2.85$28,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Cytori Therapeutics (NASDAQ:CYTX)
DateHeadline
06/26/16 08:36 AMCytori Therapeutics DE (NASDAQ:CYTX) Shorted Shares Increased By 58.61% - Press Telegraph
06/23/16 08:14 AMNew Broker Ratings For Cytori Therapeutics Inc (CYTX) - FTSE News
06/20/16 01:18 PMETF’s with exposure to Cytori Therapeutics, Inc. : June 20, 2016 -
06/18/16 03:15 PMCytori Therapeutics Inc (CYTX) Drops 5.56% on June 16 - Equities.com
06/15/16 04:09 PMCytori Closes Rights Offering for Gross Proceeds of $17.1 Million - [at noodls] - SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. ('Cytori' or the 'Company') (NASDAQ: CYTX) announced today the closing of its rights offering ('Rights Offering') to subscribe for units at a subscription ...
06/15/16 04:07 PMCYTORI THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/15/16 03:35 PMCytori announces expiration of rights offering - Seeking Alpha
06/15/16 03:35 PMHC Stocks Impression: Cytori Therapeutics Inc (NASDAQ:CYTX), Ionis Pharmaceuticals Inc (NASDAQ:IONS) - share market updates (press release)
06/13/16 03:21 PMCytori Therapeutics (CYTX) Slides on Expiration of Rights
06/13/16 09:37 AM10 Stocks Moving In Monday's Pre-Market Session
06/13/16 09:37 AMCytori Therapeutics expects US$17.1mln from share issue
06/13/16 06:19 AMCytori Announces Expiration of Rights Offering and Estimated Gross Proceeds of $17.1 Million - [at noodls] - SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. ('Cytori' or the 'Company') (NASDAQ: CYTX) announced today that the subscription period for its previously announced rights offering (the 'offering') ...
06/10/16 03:39 PMCompany Update (NASDAQ:CYTX): Cytori Therapeutics Inc Cell Therapy Leads to Improved Function and Reduced ... - Smarter Analyst
06/10/16 06:19 AMCytori Cell Therapy™ Leads to Improved Function and Reduced Scar Tissue in a Urinary Injury Model - [at noodls] - SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today the publication in The Journal of Urologyof a preclinical study applying Adipose-Derived Regenerative Cells (ADRCs) ...
06/09/16 10:49 AMWhich way Cytori Therapeutics, Inc. (NASDAQ:CYTX) earnings may go - iStreetWire
06/08/16 10:16 AMCompany Update (NASDAQ:CYTX): Cytori Therapeutics Inc To Present Twelve Month Pilot Trial Data of Cytori® Cell ... - Smarter Analyst
06/07/16 03:38 PMStock Update (NASDAQ:CYTX): Cytori Therapeutics Inc Announces Enrollment Completion in US Phase III ... - Smarter Analyst
06/07/16 10:57 AMCytori Reports Enrollment Completion In U.S. Phase III Scleroderma Trial
06/07/16 06:18 AMCytori Announces Enrollment Completion in U.S. Phase III Scleroderma Trial - [at noodls] - SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced completion of enrollment for its U.S. FDA approved Phase III STAR trial. A total of 88 patients were enrolled ahead ...
06/06/16 06:08 AMCytori Extends Rights Offering Subscription Period to Friday, June 10, and Adjusts Unit Pricing - [at noodls] - Investors Invited for a Update Call on Monday, June 6 SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today it has extended the subscription period and adjusted the subscription ...
06/06/16 06:03 AMCYTORI THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
06/02/16 03:41 PMBroker Watchlist: Cytori Therapeutics Inc (CYTX) - Share Trading News - Broker Watchlist: Cytori Therapeutics Inc (CYTX)Share Trading News04/06/2015 – Cytori Therapeutics Inc had its “buy” rating reiterated by analysts at Laidlaw. They now have a USD 4 price target on the stock. The share price of Cytori Therapeutics Inc (CYTX) was unchanged +0.00% during the last trading session, with a ...Cytori Therapeutics DE (NASDAQ:CYTX) Short Interest Increased By 12.92%The Postall 2 news articles »
05/31/16 03:36 PMStock Update (NASDAQ:CYTX): Cytori Therapeutics Inc Announces Commencement of Subscription Period for ... - Smarter Analyst - Smarter AnalystStock Update (NASDAQ:CYTX): Cytori Therapeutics Inc Announces Commencement of Subscription Period for ...Smarter AnalystCytori Therapeutics Inc (NASDAQ:CYTX) announced it has commenced the subscription period for its previously announced rights offering of up to 6,896,551 units consisting of shares of common stock and warrants to purchase shares of common stock to ...Cytori Therapeutics Inc (NASDAQ:CYTX) 1-Year High At $11.25Vanguard TribunePRGX Global, Inc. (NASDAQ:PRGX) rose 2.04%: Cytori Therapeutics, Inc. (NASDAQ:CYTX), Pinnacle Financial ...Benchmark MonitorCytori Announces Commencement of Subscription Period for Previously Announced Rights OfferingBusiness Wire (press release)all 4 news articles »
05/31/16 06:22 AMCytori Announces Commencement of Subscription Period for Previously Announced Rights Offering - [at noodls] - SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today it has commenced the subscription period for its previously announced rights offering of up to 6,896,551 units consisting ...
05/31/16 06:06 AMCYTORI THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibi -
05/28/16 10:18 AMSabby Management LLC Decreased Stake in Cytori Therapeutics INC (NASDAQ:CYTX) by $9.84 Million as Shares ... - CCH Daily News - Sabby Management LLC Decreased Stake in Cytori Therapeutics INC (NASDAQ:CYTX) by $9.84 Million as Shares ...CCH Daily NewsHal Mintz decreased its stake in Cytori Therapeutics Inc (NASDAQ:CYTX) by 57.4% based on its latest 2016Q1 regulatory filing with the SEC. Sabby Management Llc sold 9.84 million shares as the company's stock declined 92.63% while stock markets rallied ...and more »
05/25/16 10:48 AMCytori Therapeutics (CYTX) Reaches Target Enrollment in Phase III STAR Trial - StreetInsider.com - Cytori Therapeutics (CYTX) Reaches Target Enrollment in Phase III STAR TrialStreetInsider.comCytori Therapeutics, Inc. (Nasdaq: CYTX) announced that its U.S. FDA-approved phase III STAR trial has enrolled its 80th patient (100% of target enrollment). All 80 patients enrolled thus far in both trial arms have been successfully treated without ...and more »
05/25/16 06:16 AMCytori Fully Enrolls Pivotal U.S. Phase III Scleroderma Trial - [at noodls] - SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that its U.S. FDA-approved phase III STAR trial has enrolled its 80 patient (100% of target enrollment). All 80 patients ...
05/23/16 12:54 PMHC Stocks Movements Activity: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Cytori Therapeutics Inc (NASDAQ:CYTX) - share market updates (press release) - HC Stocks Movements Activity: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Cytori Therapeutics Inc (NASDAQ:CYTX)share market updates (press release)Shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) ended Friday session in green amid volatile trading. The shares closed up +0.09 points or 1.17% at $7.75. Post opening the session at $7.68, the shares hit an intraday low of $7.59 and an intraday ...and more »
05/21/16 10:48 AMCytori Therapeutics Inc (CYTX) Jumps 5.32% on May 20 - Equities.com - Cytori Therapeutics Inc (CYTX) Jumps 5.32% on May 20Equities.comCytori Therapeutics Inc (CYTX) was among the biggest gainers on the Russell 2000 for Friday May 20 as the stock popped 5.32% to $2.97, representing a gain of $0.15 per share. Some 189,543 shares traded hands on 638 trades, compared with an average ...and more »
05/19/16 01:31 PMCan A Rights Issue Save Cytori Therapeutics Inc. (NASDAQ:CYTX)? - Scibility Media - Scibility MediaCan A Rights Issue Save Cytori Therapeutics Inc. (NASDAQ:CYTX)?Scibility MediaTo participate in Cytori Therapeutics Inc. (NASDAQ: CYTX)'s rights issue; you must have been an investor in the company by the close of business on May 17, 2016. Those who didn't get into the stock before that date are out of luck, according to the ...Healthcare Stock Top loser of Week: Cytori Therapeutics, Inc.'s (CYTX)Is storiesStocks Recent Trading Summary: PDL BioPharma, Inc. (NASDAQ:PDLI) , Cytori Therapeutics Inc (NASDAQ:CYTX)Street UpdatesCytori Therapeutics Inc (NASDAQ:CYTX) Performance UpdateNews OracleWall Street Hints and News -KC Register -Seneca Globeall 8 news articles »
05/19/16 12:04 PMCYTORI THERAPEUTICS, INC. Financials -
05/18/16 09:25 PMETF’s with exposure to Cytori Therapeutics, Inc. : May 19, 2016 -
05/18/16 11:35 AMSelling Boundary Nears To- Cytori Therapeutics (NASDAQ:CYTX), Trimble Navigation (NASDAQ:TRMB), AstraZeneca ... - Seneca Globe - Selling Boundary Nears To- Cytori Therapeutics (NASDAQ:CYTX), Trimble Navigation (NASDAQ:TRMB), AstraZeneca ...Seneca GlobeCytori Therapeutics, Inc. (NASDAQ:CYTX) was among the active mover of the day as shares jumped up 35.92% to settle at $3.33. Cytori Therapeutics, Inc. (CYTX) declared that an informational update to stockholders regarding its recent rights offering and ...
05/18/16 11:35 AMStocks Recent Trading Summary: PDL BioPharma, Inc. (NASDAQ:PDLI) , Cytori Therapeutics Inc (NASDAQ:CYTX) - Street Updates - Stocks Recent Trading Summary: PDL BioPharma, Inc. (NASDAQ:PDLI) , Cytori Therapeutics Inc (NASDAQ:CYTX)Street UpdatesCytori Therapeutics Inc (NASDAQ:CYTX) after beginning at $2.42, closed at $3.33 by building up +35.92% in recent trading session. Most recent session's volume of 1.1 million shares greater than its average volume of 161.55 thousand shares. The company ...Cytori Therapeutics Inc (NASDAQ:CYTX) Performance UpdateNews OracleActive Stocks in 'How' and 'Why'- NQ Mobile (NYSE:NQ), Cytori Therapeutics (NASDAQ:CYTX), Amazon.com ...Seneca GlobeActive Broker's Concerns In Focus: AbbVie (NYSE:ABBV), Cytori Therapeutics (NASDAQ:CYTX), Mobileye (NYSE:MBLY)Street Wise Report (press release) (blog)all 4 news articles »
05/18/16 11:35 AMCytori Therapeutics Inc (CYTX) Drops 7.89% on May 16 - Equities.com - Cytori Therapeutics Inc (CYTX) Drops 7.89% on May 16Equities.comCytori Therapeutics Inc (CYTX) was one of the Russell 2000's biggest losers for Monday May 16 as the stock slid 7.89% to $2.45, a loss of $-0.21 per share. Starting at an opening price of $2.61 a share, the stock traded between $2.42 and $2.65 over the ...and more »
05/17/16 08:05 PMCytori Therapeutics Inc (CYTX) Jumps 35.92% on May 17 - Equities.com - Cytori Therapeutics Inc (CYTX) Jumps 35.92% on May 17Equities.comCytori Therapeutics Inc (CYTX) was among the biggest gainers on the Russell 2000 for Tuesday May 17 as the stock popped 35.92% to $3.33, representing a gain of $0.88 per share. Some 1.09 million shares traded hands on 3,274 trades, compared with an ...and more »
05/17/16 01:26 PMCytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/17/16 01:16 PMCytori Therapeutics Announces Important Dates In Respect Of Rights Offering - Cytori Therapeutics, Inc. (NASDAQ: CYTX) provided an update to its stockholders in respect of its recent rights offering, as well as the key dates relative to the offering. According to the company, Stockholders were advised to ensure they own the stock as of 4:00 p.m. ET on May 17, to be considered a stockholder of record on May 20, 2016. In effect, the ...Full story available on Benzinga.com
05/17/16 01:10 PMCytori Therapeutics Announces Important Dates In Respect Of Rights Offering - Benzinga - Smarter AnalystCytori Therapeutics Announces Important Dates In Respect Of Rights OfferingBenzingaCytori Therapeutics, Inc. CYTX 30.61% provided an update to its stockholders in respect of its recent rights offering, as well as the key dates relative to the offering. According to the company, Stockholders were advised to ensure they own the stock ...Company Update (NASDAQ:CYTX): European Scleroderma Trial Investigating Cytori Therapeutics Inc Cell Therapy to ...Smarter AnalystCytori Therapeutics Provides information On Shareholders Rights Offering (NASDAQ:CYTX)Sonoran Weekly ReviewCytori Therapeutics, Inc. (CYTX) Files Form 4 Insider Buying : John David Harris Buys 2000 SharesMarket Digestshare market updates (press release) -Seeking Alpha -Business Wire (press release)all 7 news articles »
05/17/16 11:42 AMCompany Update (NASDAQ:CYTX): European Scleroderma Trial Investigating Cytori Therapeutics Inc Cell Therapy to ... - Smarter Analyst - Smarter AnalystCompany Update (NASDAQ:CYTX): European Scleroderma Trial Investigating Cytori Therapeutics Inc Cell Therapy to ...Smarter AnalystCytori Therapeutics Inc (NASDAQ:CYTX) announced that on May 18, 2016, an update regarding the French SCLERADEC I and II clinical trials investigating the use of Cytori Cell Therapy in the treatment of scleroderma-related hand dysfunction will be ...Cytori Therapeutics Announces Important Dates In Respect Of Rights OfferingBenzingaCytori Therapeutics, Inc. (CYTX) Files Form 4 Insider Buying : John David Harris Buys 2000 SharesMarket DigestNoteworthy HC Stocks: Amgen, Inc. (NASDAQ:AMGN), Celgene Corporation (NASDAQ:CELG), Cytori Therapeutics Inc ...share market updates (press release)Sonoran Weekly Review -Seeking Alpha -Business Wire (press release)all 7 news articles »
05/17/16 07:42 AMEuropean Scleroderma Trial Investigating Cytori Cell Therapy to Be Presented in Japan - [at noodls] - SAN DIEGO & TOKYO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that on May 18, 2016, an update regarding the French SCLERADEC I and II clinical trials investigating the use ...
05/17/16 07:42 AMCytori Informs Stockholders of Key Dates Related to Announced Rights Offering - [at noodls] - SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NASDAQ: CYTX) today provided an informational update to stockholders regarding its recent rights offering and the key dates relative to the offering. ...
05/17/16 06:03 AM7:03 am Cytori Therapeutics will present an update regarding the use of its Cytori CEll Therapy in the French SCLERADEC I and II clinical trials at the Annual Meeting of the Japan Society of Aesthetic Surgery -
05/16/16 12:46 PMHC Stocks Watchful: Cytori Therapeutics Inc (CYTX), Transition Therapeutics Inc (TTHI), StemCells Inc (STEM) - share market updates (press release) - share market updates (press release)HC Stocks Watchful: Cytori Therapeutics Inc (CYTX), Transition Therapeutics Inc (TTHI), StemCells Inc (STEM)share market updates (press release)Shares of Cytori Therapeutics Inc (NASDAQ:CYTX) ended Friday session in red amid volatile trading. The shares closed down -0.05 points or -1.85% at $2.66 with 389,930.00 shares getting traded. Post opening the session at $2.71, the shares hit an ...Cytori Therapeutics DE (NASDAQ:CYTX) Shorted Shares Decreased By 11.45%Franklin IndependentAnalyst PT Highlights: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Cytori Therapeutics Inc (NASDAQ:CYTX)WsNews 4investorsall 5 news articles »
05/15/16 12:30 PMAfter Last Week What Do Analysts Think Of Cytori Therapeutics Inc (CYTX) - Share Trading News - After Last Week What Do Analysts Think Of Cytori Therapeutics Inc (CYTX)Share Trading News04/06/2015 – Cytori Therapeutics Inc had its “buy” rating reiterated by analysts at Laidlaw. They now have a USD 4 price target on the stock. The share price of Cytori Therapeutics Inc (CYTX) was down -1.85% during the last trading session, with a day ...Cytori Therapeutics DE (NASDAQ:CYTX) Shorted Shares Decreased By 11.45%Franklin IndependentAnalyst PT Highlights: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Cytori Therapeutics Inc (NASDAQ:CYTX)WsNews 4investorsall 3 news articles »
05/15/16 02:06 AMCytori Therapeutics Inc. (NASDAQ:CYTX) announced that the European Commission has granted orphan drug - Inside Trade - share market updates (press release)Cytori Therapeutics Inc. (NASDAQ:CYTX) announced that the European Commission has granted orphan drugInside TradeCytori Therapeutics Inc. (NASDAQ:CYTX) announced that the European Commission has granted orphan drug status to a broad range of Cytori Cell Therapy® formulations when used for the treatment of hand dysfunction and Raynaud's Phenomenon in ...Analyst Coverage: Cytori Therapeutics Inc (CYTX)Risers & FallersHC Stocks Momentum: Cytori Therapeutics Inc (CYTX), Synergy Pharmaceuticals Inc (SGYP), Novavax, Inc. (NVAX)share market updates (press release)all 3 news articles »
05/13/16 12:17 PMTrading News Morning Top Movers – CYTX, CNV, JACK, BSTG, SPCB, ARGS, RVLT - Cytori Therapeutics Inc (CYTX) traded at $3.11 + 2.89 (1,284.36 pct) on 26,981 total stock volume. The company is +12.25 pct year-to-date, and +330.60 pct during the past four quarters. Cnova N.V. (CNV) traded at $4.85 + 1.45 (42.65 pct) on 46,287 total ...
05/13/16 07:06 AMCytori Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CYTX-US : May 13, 2016 -
05/12/16 12:20 PMTwo Stocks within Analysts Review: Pfizer, Inc. (NYSE:PFE) , Cytori Therapeutics Inc (NASDAQ:CYTX) - Street Updates - Two Stocks within Analysts Review: Pfizer, Inc. (NYSE:PFE) , Cytori Therapeutics Inc (NASDAQ:CYTX)Street UpdatesPfizer, Inc. (NYSE:PFE) diminished -1.01%, closing at $33.16 after floating between $33.15 and $33.56. The company has market capitalization of $204.70B. It has twelve month low of $28.25 and twelve month high of $36.46. The recent traded volume of ...and more »
About Cytori Therapeutics

Cytori Therapeutics logoCytori Therapeutics, Inc. (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns combined with radiation injury. The Company commercializes the Celution System under select medical device approvals, clearances and registrations to research customers developing new therapeutic applications for Cytori Cell Therapy in Europe, Japan and other regions. The Company offers ECCO-50, a cure for knee osteoarthritis, which is in ECCO-50 Phase IIA/B of development. It offers ECCI-50, a cure for urinary incontinence, which is in Phase II/III of development. The Company is also developing DCCT-10, a cure for cutaneous thermal injury.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CYTX
  • CUSIP: 23283K10
Key Metrics:
  • Previous Close: $2.02
  • 50 Day Moving Average: $2.66
  • 200 Day Moving Average: $3.04
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $26.93M
  • Current Quarter EPS Consensus Estimate: $-1.78 EPS
Additional Links:
Cytori Therapeutics (NASDAQ:CYTX) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha